Quince Therapeutics (QNCX) Appoints Charles S. Ryan as President

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced the appointment of Charles S. Ryan, J.D., Ph.D. as President. In this new position, Dr. Ryan will be responsible for the company’s corporate legal activities and intellectual property portfolio, and pending the completion of its planned acquisition of EryDel S.p.A., the international integration of financial and operational activities and ongoing business operations of Quince.

Dirk Thye, M.D., Quince’s Chief Executive Officer, said, “Charles is a valuable addition to our management team. His considerable expertise will help enhance efficiency and effectiveness across our research programs and business operations. I have known Charles and his work for many years, during which he has repeatedly demonstrated a broad and impressive skill set in many areas of business, research, and law. His contributions to the ongoing management of our legal, IP, and upon completion, the integration of the Italian business and ongoing operations, will be critical in both the near and longer term.”

Dr. Ryan, Quince’s President, said, “Quince and the EryDel assets would represent an exciting opportunity to advance a first-to-market treatment for pediatric patients suffering from the fatal rare neurological disease, Ataxia-Telangiectasia (A-T). Pending completion of the transaction, I look forward to working closely with Quince’s management and talented EryDel team to advance a potentially breakthrough therapy to these long-underserved patients.”

Dr. Ryan brings an extensive background in pharmaceuticals and biotechnology. Most notably, he served as Senior Vice President and Chief Intellectual Property Counsel at Forest Laboratories (now AbbVie) for more than 10 years where he managed several intellectual property estates spanning CNS, cardiovascular, gastrointestinal, respiratory, and anti-infective therapeutic areas. He also worked closely with the commercial and development teams, as well as the business development teams at Forest.

Most recently, Dr. Ryan served as President, Chief Executive Officer, and Chairman of Travecta Therapeutics, a private biopharmaceutical company pioneering transformative treatments for serious neurological conditions. Prior to that, he served as Chief Executive Officer and Director of Neurotrope, Inc., a clinical-stage biopharmaceutical company developing targeted, novel regenerative therapeutics for neurodegenerative diseases and developmental disorders. Dr. Ryan holds a J.D. from Western New England University, a Ph.D. in Oral Biology and Pathology from Stony Brook University, and a B.A. in Chemistry from The College of Wooster. He is a member of the New York State Bar and is a patent practitioner of the U.S. Patent and Trademark Office.

You May Also Be Interested In

• Kimbell Royalty closes $221.2M mineral rights acquisition
• Home Depot expands executive roles, grants $500K in restricted stock
• Nu Skin EVP of global sales takes medical leave